^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:toremifene (Selective estrogen receptor modulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/12/2017
    Excerpt:
    FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Breast Cancer Res Treat
    Title:

    A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer

    Excerpt:
    In postmenopausal women, toremifene 60 mgdaily is an effective and safe treatment ofadvanced ER-positive or ER-unknown breast cancer.
    DOI:
    10.1023/A:1005891506092
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Br J Cancer
    Title:

    Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.

    Excerpt:
    Four hundred and fifteen post-menopausal patients with oestrogen receptor (ER)-positive or ER-unknown advanced breast cancer were randomly assigned to receive daily either 60 mg TOR or 40 mg TAM...In conclusion, TOR (60 mg day(-1)) and TAM (40 mg day(-1)) are equally effective and safe in the treatment of advanced post-menopausal ER-positive or ER-unknown breast cancer.
    DOI:
    10.1038/bjc.1997.375